Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra)
- PMID: 16841199
- DOI: 10.1007/s11095-006-9007-4
Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra)
Abstract
Purpose: To develop a model to explore the dose-response of sildenafil citrate in patients with female sexual arousal disorder (FSAD) based on telephone sexual activity daily diary (TSADD) data obtained in double-blind, placebo controlled clinical studies.
Materials: Data were available on 614 patients with FSAD. A parametric model (Weibull distribution) was developed to describe the probability density function of the time between sexual events. Orgasm satisfaction scores and overall sexual satisfaction scores were simultaneously modeled as ordered categorical variables. Simulations were performed to evaluate the expected clinical response in patients with FSAD.
Results: The expected time between sexual events was approximately 3.5 days. Satisfaction scores increased with time to achieve a plateau after 3 to 4 weeks on treatment. The expected probability of satisfying orgasm (score of 3 and higher) ranged from 34.7% for placebo to 41.6% for 100 mg sildenafil citrate. Treatment effect (difference from placebo) was 6.9% for 100 mg sildenafil citrate, ranging from 0.6 to 24.7% for testosterone levels of 0.1 to 4.0 pg/ml. The treatment effect in postmenopausal women was larger than in premenopausal women.
Conclusion: A modeling and simulation framework to support drug development in FSAD was developed. Sildenafil citrate demonstrated a dose-dependent effect in patients with FSAD.
Similar articles
-
Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study.J Urol. 2003 Dec;170(6 Pt 1):2333-8. doi: 10.1097/01.ju.0000090966.74607.34. J Urol. 2003. PMID: 14634409 Clinical Trial.
-
Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.J Womens Health Gend Based Med. 2002 May;11(4):367-77. doi: 10.1089/152460902317586001. J Womens Health Gend Based Med. 2002. PMID: 12150499 Clinical Trial.
-
Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial.BJOG. 2003 Nov;110(11):1014-24. BJOG. 2003. PMID: 14592587 Clinical Trial.
-
Sildenafil citrate for female sexual arousal disorder: a future possibility?Nat Rev Urol. 2009 Apr;6(4):216-22. doi: 10.1038/nrurol.2009.25. Nat Rev Urol. 2009. PMID: 19352396 Review.
-
Sexual dysfunction and depression.Curr Psychiatry Rep. 2001 Jun;3(3):202-8. doi: 10.1007/s11920-001-0053-7. Curr Psychiatry Rep. 2001. PMID: 11353583 Review.
Cited by
-
Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.Curr Oncol. 2007 Dec;14 Suppl 1(Suppl 1):S20-40. doi: 10.3747/co.2007.151. Curr Oncol. 2007. PMID: 18087605 Free PMC article.
-
Pharmacodynamic models for discrete data.Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Clin Pharmacokinet. 2012. PMID: 23179578 Review.
-
[Lifestyle drugs in medicine].Wien Med Wochenschr. 2008;158(3-4):110-5. doi: 10.1007/s10354-007-0473-z. Wien Med Wochenschr. 2008. PMID: 18330527 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical